SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib?ABSK021? has been granted orphan drug designation?ODD? by the European Medicines Agency (EMA) for the treatment of inoperable tenosynovial giant cell tumor (TGCT).
Merck KGaA, Darmstadt, Germany Strengthens Oncology Portfolio